Objectives: We aimed to determine quantitative photon-counting CT (PCCT)-derived iodine map (IM) attenuation associated with visual detectability of parenchymal hyperattenuation on conventional brain window (BW) images after mechanical thrombectomy (MT) and to assess corresponding relative BW attenuation changes. Methods: In this retrospective single-center study, 12 patients with anterior circulation large vessel occlusion underwent MT followed by post-interventional PCCT. BW, IM, and virtual non-contrast reconstructions were generated. Follow-up non-contrast CT served as reference for final infarction extent. Of 54 ASPECTS regions with final infarction, 40 showed IM hyperattenuation and were included in the detectability analysis. Two blinded readers assessed visual detectability. IM attenuation and relative BW attenuation increase (%ΔHU) were evaluated using ROC analysis with clustered bootstrap resampling. Thresholds were determined using the Youden index. Results: Across all 54 regions with final infarction, median IM attenuation was significantly higher in infarcted than contralateral regions (6.39 vs. 2.18 HU, p < 0.001), while absolute BW attenuation did not differ significantly. Among the 40 regions with IM hyperattenuation, 15 were visually detectable on BW images. ROC analysis showed excellent performance for IM (AUC = 0.997) and %ΔHU (AUC = 0.984). The optimal IM threshold in the original cohort was 8.33 HU (sensitivity 100%, specificity 96.0%), and the optimal %ΔHU threshold was 3.06% (sensitivity 100%, specificity 92.0%). Bootstrap-derived median thresholds were 11.69 HU (95% interval 8.33–12.67) for IM and 3.06% (3.06–20.16%) for %ΔHU. Inter-reader agreement was excellent (κ = 0.81–0.86). Conclusions: PCCT-derived iodine quantification enables objective assessment of visual detectability of post-interventional parenchymal hyperattenuation. In this cohort, an internally derived IM cutoff of 8.33 HU was associated with BW visibility. These preliminary findings require validation in larger, independent multicenter cohorts.
Background: Intracranial arterial calcification (IAC), commonly detected on CT/CTA during ischemic stroke work-up, may reflect atherosclerotic burden relevant to recurrence. We evaluated whether CTA-detected IAC was associated with subsequent ischemic cerebral events. Methods: This retrospective single-center cohort included patients with ischemic stroke or transient ischemic attack admitted to a tertiary stroke unit between 2010 and 2023. IAC was assessed on index-event CTA using volumetric quantification and the Babiarz score. Time to first recurrent ischemic cerebrovascular event was analyzed using multivariable Cox regression. Robustness was evaluated through adjustment for stroke etiology and CTA acquisition parameters, penalized regression, bootstrap internal validation, and competing-risk analysis accounting for death. Results: Among 556 patients (median age, 71.5 years [IQR, 62.3–78.6]; 354 male), 60 (10.8%) experienced recurrence during a median follow-up of 3.5 years (IQR, 1.8–7.5). Median IAC volume was higher in patients with recurrence than in those without recurrence (45.0 mm3 [IQR, 14.1–143.2] vs. 18.3 mm3 [IQR, 0–105.6]; p = 0.01). A one-unit increase in log10(IAC + 1), corresponding to a tenfold increase in IAC + 1, was associated with a higher recurrence hazard (HR, 1.63; 95% CI, 1.18–2.24; p = 0.003). The model had a C-index of 0.727, and the association remained consistent across sensitivity analyses. Babiarz scores correlated strongly with volumetric IAC measurements in the intracranial carotid and vertebral arteries (ρ ≥ 0.93; p < 0.01). Conclusions: Greater CTA-derived IAC burden was associated with a higher hazard of recurrent ischemic cerebrovascular events. Quantitative IAC assessment warrants further investigation as a potential imaging marker of recurrence risk, although external validation is required before clinical implementation.